Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy - Wikidata - awgldk - TriplyDB

Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy

Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy

http://www.wikidata.org/entity/Q34810257

about

Overcoming Hypoxia-Mediated Tumor Progression: Combinatorial Approaches Targeting pH Regulation, Angiogenesis and Immune Dysfunction Cancer-Associated Myeloid Regulatory Cells Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients.The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy.Transcriptional regulation of myeloid-derived suppressor cells.ROR1C Regulates Differentiation of Myeloid-Derived Suppressor Cells Relevance of Interferon Regulatory Factor-8 Expression in Myeloid-Tumor Interactions.TRPM8: a potential target for cancer treatment.Total cellular protein presence of the transcription factor IRF8 does not necessarily correlate with its nuclear presence.Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy.Selective Targeting of Myeloid-Derived Suppressor Cells in Cancer Patients Using DS-8273a, an Agonistic TRAIL-R2 Antibody.Mechanisms overseeing myeloid-derived suppressor cell production in neoplastic disease.The Dr. Jekyll and Mr. Hyde complexity of the macrophage response in disease.Myeloid-Derived Suppressor Cells.High-mobility group box protein 1 promotes the survival of myeloid-derived suppressor cells by inducing autophagy.Immunosuppressive Myeloid Cells' Blockade in the Glioma Microenvironment Enhances the Efficacy of Immune-Stimulatory Gene Therapy.Cancer-Associated Fibroblasts Neutralize the Anti-tumor Effect of CSF1 Receptor Blockade by Inducing PMN-MDSC Infiltration of Tumors.Myeloid-Derived Suppressor Cells: Immune-Suppressive Cells That Impair Antitumor Immunity and Are Sculpted by Their Environment.The Granulocyte Progenitor Stage Is a Key Target of IRF8-Mediated Regulation of Myeloid-Derived Suppressor Cell Production.The immunomodulatory, antitumor and antimetastatic responses of melanoma-bearing normal and alcoholic mice to sunitinib and ALT-803: a combinatorial treatment approach.Peripheral T cell responses to tumour antigens are associated with molecular, immunogenetic and cellular features of breast cancer patients.Prognostic role of pretreatment circulating MDSCs in patients with solid malignancies: A meta-analysis of 40 studies

P2860

Q26749333-119DD6D5-0CF4-49F2-BF69-C69E80791E41 Q26750382-AB85CBAC-6F9D-4294-84B4-381529D61359 Q28084627-D93CC561-AB88-4CD7-AE06-631D9FD33A0E Q28388630-10B36FE3-0974-4253-A477-1F570433DF4E Q33564156-05FC3B1D-B8FD-4BE7-AD54-34C7B70C3049 Q33660069-E20DE77F-29DB-4947-B478-B070909ABD1B Q36322351-9C0EF1CA-9DAC-412E-AA8F-4FC26E2A6C40 Q36345203-A771CB2D-6495-46BD-93F4-063A48733B99 Q37062216-1CABC78F-A93B-4E19-BE5C-A24A4E7C141E Q38709214-89E55FFA-A173-4B87-9570-122BC502C15E Q38748747-DADF3AA5-92B4-4348-B685-D99BB8283F1F Q38989773-F4FBF783-A167-4DA7-ABE2-472A069529CB Q39103948-FBE4BACC-6D1F-4BAC-B274-8AE986E765CD Q39146128-43EC3BE7-11FB-46D1-A978-C50CA37F614B Q39188002-FA6186F1-59CB-411D-9F19-D55AEDFBB85A Q40385399-526A8D43-121F-4E77-B7D5-EB0EB63A2025 Q42360945-DA7190E0-147C-4F78-BC08-1005233BCAD2 Q45864012-03BF9FD1-2E59-4B2C-932B-66D815ADB21C Q47404669-449A4963-3ADE-411E-A99C-1C6EC94E50FF Q48293607-151E7C1A-BDF2-4840-A9B5-B939F45E70E0 Q48347565-7AA13806-3857-44D1-A357-6DF205547EF1 Q50632502-EE16E21F-339D-4E70-8DA6-A20A6E8BE8EB Q51359999-6A32AFFC-0871-4E7B-9985-465EA6EC4CCF Q57138311-8AD2FDAF-EB67-4E68-A48A-A6B32099E30A

P2860

Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy

http://www.wikidata.org/entity/Q34810257

description

2014 nî lūn-bûn

@nan

2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy

@ast

Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy

@en

Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy

@nl

type

label

Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy

@ast

Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy

@en

Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy

@nl

prefLabel

Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy

@ast

Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy

@en

Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy

@nl

P1433

Q34810257-A846CC23-5932-40AF-B84E-D415AB108CBE

P1476

Q34810257-19B8814D-292E-4684-B5D7-A357DC44B17F

P2093

Q34810257-7B3433AE-ED32-4C69-9AAE-ACDA8EC8B50F

Q34810257-DBAFBD49-1BD6-41BE-8B8A-8572D4CE999B

Q34810257-DE6C2D71-120D-473B-88B4-08F3B4BDE8B6

P2860

Q34810257-07312A45-B6B1-4CDD-808E-C846274ABE31

Q34810257-0837EE2D-59ED-4C91-B428-02FD04B9BF0F

Q34810257-0953CC90-BEE1-4C35-9CA4-76F9DD2879A0

Q34810257-0B4AA724-9F5F-4B6D-877A-F162C89A023F

Q34810257-0C69A2E4-C9C7-456B-8FAA-AE377E78A035

Q34810257-13CD4A68-1AA8-4D7B-9962-C526D20CF4C2

Q34810257-1635E302-E7B7-4C4B-9EFC-3862431F32B2

Q34810257-1805FAA6-0DE1-4B21-8F5F-3F0633CBACFC

Q34810257-1ACFFBA7-9952-4F5C-AA78-4838998CE94E

Q34810257-1B147F1B-A8B9-4C9B-B9B4-D706C6E94ED6

P2888

Q34810257-6429BF65-C246-4948-A481-C2610E602AC7

P304

Q34810257-A8AADF91-8EAC-4E7D-8708-3653BC8D14D6

P31

Q34810257-E267DA2F-3038-4899-81BE-E3A49359E378

P356

Q34810257-F780FDA8-D932-49C0-8D29-6AAE6340F99F

P433

Q34810257-16275731-C6D4-4907-BE92-1F9A3B5B32B6

P478

Q34810257-D7EC6F73-7984-4B52-A0A5-B00B05FA3E39

P50

Q34810257-AFD31A93-7115-4380-A2C0-C04FE8253284

P577

Q34810257-877781FF-94D1-4883-8268-795D5DFE4C56

P6179

Q34810257-80033EEC-93F6-428A-BF28-A58DF680DEC5

P698

Q34810257-01738167-3D8C-4FAA-9501-E93E5966261B

P921

Q34810257-20006EFF-4DC0-40DC-9807-E4853E2DE47D

P932

Q34810257-FB273BE9-0207-4CBB-B061-F63D10660619

P356

S00262-014-1639-3

P1433

Cancer Immunology, Immunotherapy

P1476

Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy

@en

P2093

Colleen S Netherby

http://www.w3.org/2001/XMLSchema#string

Debarati Banik

http://www.w3.org/2001/XMLSchema#string

Scott I Abrams

http://www.w3.org/2001/XMLSchema#string

P2860

Mechanisms of immune suppression in patients with head and neck cancer: presence of CD34(+) cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor

The Hallmarks of Cancer

Hallmarks of Cancer: The Next Generation

Human interferon consensus sequence binding protein is a negative regulator of enhancer elements common to interferon-inducible genes

Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene

ICSBP is essential for the development of mouse type I interferon-producing cells and for the generation and activation of CD8alpha(+) dendritic cells

Inflammatory modulation of HSCs: viewing the HSC as a foundation for the immune response

Myeloid-derived suppressor cells as regulators of the immune system

ICSBP/IRF-8: its regulatory roles in the development of myeloid cells

Inhibition of monocytic differentiation by phosphorylation-deficient Stat1 is associated with impaired expression of Stat2, ICSBP/IRF8 and C/EBPepsilon

P2888

s00262-014-1639-3

P304

1-13

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00262-014-1639-3

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

64

http://www.w3.org/2001/XMLSchema#string

P50

Michelle Messmer

P577

2014-11-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1019968300

http://www.w3.org/2001/XMLSchema#string

P698

25432147

http://www.w3.org/2001/XMLSchema#string

P921

P932

4282948

http://www.w3.org/2001/XMLSchema#string